Vaccines Market

The vaccines market is experiencing sustained growth, driven by new product approvals, label expansions, and launches that broaden eligible populations and geographic reach. Recent regulatory activity includes the US FDA’s February 2025 approval of GSK’s PENMENVY for protection against five meningococcal serogroups in individuals aged 10–25 years and the May 2025 approval of Moderna’s next-generation mRNA COVID-19 vaccine, MNEXSPIKE. Merck’s CAPVAXIVE, first approved for adults in June 2024, was further expanded in June 2026 to include certain children and adolescents at increased pneumococcal-disease risk. Overall, continued pipeline investment, wider age-group coverage, and commercialization of differentiated vaccines remain important growth drivers for the market.

Vaccine research and development (R&D) is typically a lengthy process that is prone to failures and requires significant capital investment. Additionally, scaling up production carries high risks. Factors such as yield variability, complex analytics, and strict quality assurance and quality control (QA/QC) increase the likelihood of batch failures and the need for working capital. Unlike small-molecule drugs, vaccines require specialized process development, facilities that meet Biosafety Level (BSL) standards, and sterile biologics manufacturing, all of which are costly to build, validate, and maintain. Furthermore, regulatory requirements mandate large, well-structured prophylactic trials, leading to higher trial sizes and costs compared to many therapeutic products. This is because endpoints must demonstrate effectiveness in preventing disease within healthy populations. All of these factors contribute to a high break-even point in vaccine development.

Therapeutic vaccines are shifting the focus from disease prevention to treatment, creating valuable opportunities in oncology, chronic infections, and immune-mediated disorders. These vaccines aim to enhance T-cell responses that are specific to tumors or pathogens, making them effective partners for checkpoint inhibitors and standard treatments. As a result, clinical successes can lead to higher pricing and broader adoption. In addition to cancer, therapeutic candidates for hepatitis B virus (HBV), herpes simplex virus (HSV), and tuberculosis (TB) target large populations of chronic patients. Even achieving partial functional cures or reducing relapses in these patients would be economically beneficial and supported by health policies. The transition from public tender pediatric channels to specialty pharmacy and oncology delivery models allows for higher average selling prices (ASPs), improved outcome tracking, and bundled contracting with immunotherapies.

Vaccines are subject to stricter regulations than most other medicines, primarily because they are often administered to children. Regulators typically require extensive, multi-year studies to demonstrate that a vaccine effectively prevents disease, rather than just alleviating symptoms. This necessity leads to longer development timelines. Additionally, safety databases must be comprehensive enough to identify very rare side effects, which increases the size and cost of trials. On the manufacturing side, the Chemistry-Manufacturing-Controls (CMC) package is significant and includes components like sterility, potency, consistency, and stability, all of which require complete validation. Each batch of vaccine may also need to undergo official control or lot release testing, which can add weeks to the process and tie up inventory. Furthermore, cold-chain qualification, packaging, and country-specific labeling require separate approvals and detailed documentation.